About Kiniksa Pharmaceuticals, Ltd.
https://www.kiniksa.comKiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
CEO
Sanj K. Patel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 85
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.59M
Value:$181.63M
RUBRIC CAPITAL MANAGEMENT LP
Shares:4M
Value:$158.24M
PICTET ASSET MANAGEMENT LTD
Shares:3.33M
Value:$131.93M
Summary
Showing Top 3 of 225
About Kiniksa Pharmaceuticals, Ltd.
https://www.kiniksa.comKiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $180.85M ▲ | $73.24M ▲ | $18.43M ▲ | 10.19% ▼ | $0.25 ▲ | $27.54M ▲ |
| Q2-2025 | $156.8M ▲ | $65.62M ▲ | $17.83M ▲ | 11.37% ▲ | $0.24 ▲ | $20.52M ▲ |
| Q1-2025 | $137.78M ▲ | $62.85M ▼ | $8.54M ▲ | 6.2% ▲ | $0.12 ▲ | $13.62M ▲ |
| Q4-2024 | $122.54M ▲ | $75.66M ▲ | $-8.89M ▲ | -7.25% ▲ | $-0.12 ▲ | $-16.58M ▼ |
| Q3-2024 | $112.21M | $72.46M | $-12.69M | -11.31% | $-0.18 | $-9.26M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $352.1M ▲ | $712.33M ▲ | $176.95M ▲ | $535.38M ▲ |
| Q2-2025 | $307.78M ▲ | $661.15M ▲ | $166.14M ▲ | $495.01M ▲ |
| Q1-2025 | $268.34M ▲ | $599.33M ▲ | $141.84M ▼ | $457.49M ▲ |
| Q4-2024 | $243.63M ▲ | $580.55M ▲ | $142.12M ▲ | $438.44M ▲ |
| Q3-2024 | $223.78M | $555.3M | $118.29M | $437.01M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $18.43M ▲ | $33.68M ▲ | $-62.76M ▼ | $11.9M ▲ | $-17.18M ▼ | $33.01M ▲ |
| Q2-2025 | $17.83M ▲ | $28.09M ▲ | $-3.88M ▲ | $10.7M ▲ | $34.91M ▲ | $27.93M ▲ |
| Q1-2025 | $8.54M ▲ | $22.32M ▲ | $-51.54M ▼ | $2.77M ▲ | $-26.45M ▼ | $22.23M ▲ |
| Q4-2024 | $-8.89M ▲ | $18.77M ▲ | $65.29M ▲ | $2.14M ▼ | $86.2M ▲ | $18.58M ▲ |
| Q3-2024 | $-12.69M | $-2.24M | $-6.35M | $6.69M | $-1.9M | $-2.24M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $200.00M ▲ | $140.00M ▼ | $160.00M ▲ | $180.00M ▲ |
 Collaboration | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Sanj K. Patel
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 85
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:4.59M
Value:$181.63M
RUBRIC CAPITAL MANAGEMENT LP
Shares:4M
Value:$158.24M
PICTET ASSET MANAGEMENT LTD
Shares:3.33M
Value:$131.93M
Summary
Showing Top 3 of 225